The Comparative Safety of Various Intravenous Iron Preparations in Chronic Kidney Disease Patients

REFERENCES

• NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis. 2001; 37(Suppl. 1)S182–S238
   PubMedGoogle Scholar
• Nissenson AR, Strobos J. Iron deficiency in patients with renal failure. Kidney Int. 1999; 69(Suppl. 1)S18–S21
   Google Scholar
• Locatell F, Aljama P, Barany P, et al. Revised European best practice guidelines for management of anemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19(Suppl. 2)i22–i25
   Google Scholar
• Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis. 2001; 37: 743–749
   PubMed Web of Science ®Google Scholar
• Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant. 2004; 19: 1571–1575
   PubMed Web of Science ®Google Scholar
• Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA. 1980; 243: 1726–1731
   PubMed Web of Science ®Google Scholar
• Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006; 21: 378–382
   PubMed Web of Science ®Google Scholar
• Arnoff GR. Safety of intravenous iron in clinical practice: Implications for anemia management protocols. J Am Soc Nephrol. 2004; 15: 99–106
   Google Scholar
• Michael B, Coyne DW, Fishbane S, et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int. 2002; 61: 1830–1839
   PubMed Web of Science ®Google Scholar
• Coyne WD, Adkinson F, Jr, Nissenson Allen R, et al. SFGC in hemodialysis patients, II: Adverse reactions in iron-dextran sensitive and dextran tolerant patients. Kidney Int. 2003; 63: 217–224
   PubMed Web of Science ®Google Scholar
• Sampson HA, Munoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: Summary report. J Allergy Clin Immunol. 2005; 115: 584–591
   PubMed Web of Science ®Google Scholar
• Novey HS, Pahl M, Haydik I, et al. Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy. 1994; 72: 224–228
   Google Scholar
• Bailie GR, Clark JA. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant. 2005; 20: 1443–1449
   PubMed Web of Science ®Google Scholar
• Barton JC, Barton EH, Bertoli LF, Gothard CH, Sherrer JS. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med. 2000; 109: 27–32
   PubMed Web of Science ®Google Scholar
• Auerbach M, Witt D, Toler W, et al. Clinical use of total dose intravenous iron dextran infusion. J Lab Clin Med. 1988; 111: 566–570
   PubMed Web of Science ®Google Scholar
• McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran—a comparison of two products. Am J Nephrol. 2000; 20: 455–462
   PubMed Web of Science ®Google Scholar
• Burns DL, Pomposelli JJ. Toxicity of parenteral iron dextran therapy. Kidney Int. 1999; 55(Suppl. 69)S119–S124
   Google Scholar
• Kletzmayr J, Ferrara I. Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol. 2002; 14: 2639–2644
   Google Scholar
• Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996; 28: 529–534
   PubMed Web of Science ®Google Scholar
• Panesar A, Agarwal R. Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease. Am J Kidney Dis. 2002; 40: 924–931
   PubMed Web of Science ®Google Scholar
• Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am J Kidney Dis. 1999; 33: 471–482
   PubMed Web of Science ®Google Scholar
• Michael B, Coyne DW, Folkert VW, Daahl NV, Warnock DG. Ferrlecit Publication Committee. Sodium ferric gluconate complex in hemodialysis patients: A prospective evaluation of long-term safety. Nephrol Dial Transplant. 2004; 19: 1576–1580
   Google Scholar
• Charytan C, Levin N, Al-Saloum M, et al. Efficacy and safety of iron sucrose in iron deficiency in patients of dialysis-associated anemia: North America Clinical Trial. Am J Kidney Dis. 2001; 37(2)300–307
   Google Scholar
• Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs. iron gluconate (Ferrlecit) in hemodialysis patients treated with rHuEpo. Nephrol Dial Transplant. 2001; 16: 1239–1244
   Google Scholar
• Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron. Arzneimittel-forschung. 1992; 2(12)1439–1452
   Google Scholar
• Van Wyck DB, Cavallo G, Spinowitz BS, et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis. 2000; 36: 88–97
   PubMed Web of Science ®Google Scholar
• Aronoff GR, Bennett WM, Blumenthal S, et al. Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens. Kidney Int. 2004; 66: 1193–1198
   PubMed Web of Science ®Google Scholar
• Van Wyck DB, Danielson BG, Aronoff GR. Making sense: A scientific approach to intravenous iron therapy. J Am Soc Nephrol. 2004; 15: 91–92
   Google Scholar
• Charytan C. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clin Pract. 2004; 96(2)63–66
   Google Scholar
• Fishbane S, Kowaliski E. The comparative safety of intravenous iron dextran, sacchharate, and sodium ferric gluconate. Semin Dialysis. 2000; 13(6)381–384
   Google Scholar
• Rolla G, Bucca C, Brussino L. Systemic reactions to intravenous iron therapy in patients receiving ACE inhibitors. J Allergy Clin Immun. 1994; 93: 1074–1075
   Google Scholar